GSK reported that the FDA granted full approval for Jemperli for the treatment of adult patients with mismatch repair-deficient, or dMMR, recurrent or advanced endometrial cancer, as determined by a FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- GSK’ Jemperli gets regular approval for dMMR endometrial cancer
- FDA Oncologic Drugs Advisory Committee to hold a virtual meeting
- GSK, Cytel enter three-year agreement to expand Solara deployment
- GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler
